Genentech Logo

Oncology

Focus on Oncology

At Genentech, we take a rigorous, comprehensive approach to understanding cancer biology and drug discovery.

Our scientists are leaders in the identification of novel cell surface molecules and are working to characterize tumor antigens that may be useful in fighting various forms of cancer. These tumor antigens are used to produce sophisticated monoclonal antibodies that selectively target the desired cancer to modulate function, mark cells for destruction by the immune system, or precisely deliver lethal doses of cytotoxic compounds.

We continue to expand our expertise in angiogenesis and apoptosis - discovering new basic insights and new therapeutic opportunities. Our major research programs also include unraveling complex signaling pathways, and targeting critical aspects of the cell cycle, metabolic regulators, and the immune response to cancer. Cancer stem cells are also rapidly becoming topics of exceptional excitement and opportunity.

Recent Accomplishments

  • Genentech Medicine Approved For Advanced Basal Cell Carcinoma
    On January 30, 2012, a Genentech medicine was approved by the FDA for the treatment of adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.
    Learn More

Join Our Team

We're looking for smart, passionate people to join us.

View Careers

Pipeline

Genentech's Research and Early Development pipeline has over 25 new molecular entities in clinical development.

View Our Pipeline